NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 14:14இன்று 29 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Pfizer Q2 FY27 PAT Jumps 65.7% to ₹313.25 Cr Aided by ₹132.06 Cr One-Off Gain
Pfizer Limited reported revenue from operations of ₹726.86 crore for Q2 ended September 30, 2026, up 13.2% YoY from ₹642.34 crore. Net profit rose 65.7% YoY to ₹313.25 crore, significantly aided by an exceptional income of ₹132.06 crore received as a lump sum from Pfizer Inc. USA following the discontinuation of Minipress XL. Excluding this exceptional item, basic EPS stood at ₹47.09 per share compared to total EPS of ₹68.47. Half-year cash generation from operations was ₹358.99 crore, with bank balances outside cash equivalents standing at ₹3,077.06 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported Q2 and H1 FY27 financial results and recognized an exceptional lump sum income of ₹132.06 crore for discontinuing Minipress XL.
ஏன் இது முக்கியம்While core revenue grew 13.2% YoY, reported profits were temporarily boosted by the non-recurring ₹132.06 crore compensation; the underlying business continues to hold large cash reserves (>₹3,100 cr).
Revenue from operations (Q2): ₹726.86 கோடிNet profit (Q2): ₹313.25 கோடிExceptional gain: ₹132.06 கோடிEPS before exceptional items: ₹47.09Bank balances other than cash: ₹3,077.06 கோடி
📅 குறுகிய காலம்Headline earnings appear strong due to the one-off gain, but the market will likely adjust expectations for normalized operational profitability.
📈 நீண்ட காலம்Portfolio rationalization continues as global parent decisions phase out legacy products, leaving growth reliant on patented product launches and specialty segments.
⚠ அபாய எச்சரிக்கைகள்
Discontinuation of products (e.g., Minipress XL) impacting forward product-line revenues
One-off nature of ₹132.06 crore exceptional gain inflating current-period earnings
👀 கவனிக்க வேண்டியவை
Track organic revenue growth in the coming quarters to evaluate how the portfolio replaces discontinued volumes from Minipress XL, alongside operational margins excluding one-off income.
Pfizer to Discontinue Minipress XL; to Receive USD 13.9M (~₹131.38 Cr) Lump Sum Compensation
Pfizer Limited announced that it will discontinue the marketing, distribution, and sale of Minipress XL with effect from September 7, 2026, following parent Pfizer Inc. USA's decision to stop manufacturing the drug. In connection with the discontinuation, the company will receive a one-time lump sum payment of USD 13.9 million (~₹131.38 crore) from Pfizer Inc. USA. This compensation equates to approximately 20.1% of Pfizer Limited's Q1 FY27 revenue (₹653.17 crore in Jun 2026). While the lump sum will provide a short-term cash and profit boost, it permanently removes the revenue contribution of Minipress XL.
உச்சம் நம்பிக்கை
என்ன மாறியதுPfizer Limited has terminated the commercialization of Minipress XL in India due to manufacturing discontinuation by parent Pfizer Inc. USA.
ஏன் இது முக்கியம்Provides a one-time pre-tax cash inflow of ~₹131.38 crore, but leads to a permanent loss of recurring product sales from the portfolio.
Lump sum compensation: USD 13.9 Million (~Rs. 131.38 Crore)Effective date: செப்டம்பர் 7, 2026Compensation vs Jun 2026 revenue: ~20.1%
📅 குறுகிய காலம்The one-time payout of ~₹131.38 crore will boost other income/operating profitability in the near term once recognized.
📈 நீண்ட காலம்Limited negative impact depending on the historical revenue contribution of Minipress XL to the overall product mix.
⚠ அபாய எச்சரிக்கைகள்
Loss of recurring revenue from Minipress XL
One-off nature of compensation income
👀 கவனிக்க வேண்டியவை
Watch the upcoming quarterly financial results for the accounting treatment of the ₹131.38 crore receipt and management commentary on the recurring revenue impact from discontinuing Minipress XL.
Pfizer Approves Rs 75 Per Share Final Dividend at 75th AGM
Pfizer Limited's shareholders have officially approved all resolutions at the 75th Annual General Meeting held on July 28, 2026. The key highlight is the declaration of a final dividend of Rs 75 per equity share (750% of face value) for the financial year ended March 31, 2026. The voting results showed overwhelming support, with the dividend resolution receiving 99.9998% votes in favor. Additionally, shareholders ratified the appointment of Mr. P. Rengan as Director and the remuneration for cost auditors for FY 2026-27.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders have formally ratified the financial results for FY 2025-26 and the dividend payout proposed by the board.
ஏன் இது முக்கியம்The approval confirms a significant cash return to shareholders and ensures corporate governance continuity through the re-appointment of directors and auditors.
Final Dividend: Rs 75 per shareDividend Percentage: 750%ரெக்கார்ட் தேதி: ஜூலை 17, 2026Total Shareholders: 1,05,890Votes in Favor (Dividend): 99.9998%
📅 குறுகிய காலம்The stock may see neutral to slightly positive sentiment as the dividend is now officially confirmed for payout.
📈 நீண்ட காலம்Limited; this is a routine annual procedure confirming the company's established dividend-paying track record.
👀 கவனிக்க வேண்டியவை
Investors should note the official approval of the Rs 75 dividend and monitor the company's announcement regarding the specific payment date.
₹75 Dividend Approved at Pfizer Limited's 75th Annual General Meeting
Pfizer Limited concluded its 75th AGM on July 28, 2026, where shareholders approved a dividend of ₹75 per equity share (750%). The meeting included the adoption of audited financial statements for the year ended March 31, 2026, and the re-appointment of Mr. P. Rengan as Director. Managing Director Meenakshi Nevatia provided an overview of the company's performance, focusing on new product introductions and the specialty science portfolio. The company also ratified the remuneration for cost auditors for the 2026-27 financial year.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders formally approved the FY26 financial results and a significant dividend payout of ₹75 per share.
ஏன் இது முக்கியம்It reinforces the company's cash-return profile and provides a platform for management to update on the transition toward a patented global product portfolio.
📅 குறுகிய காலம்The stock may see neutral to positive sentiment as the ₹75 dividend is formalized, though the impact is likely already partially priced in.
📈 நீண்ட காலம்Structural focus on high-margin patented products and specialty therapies remains the key value driver for this MNC pharma player.
⚠ அபாய எச்சரிக்கைகள்
Dependency on hospital footfalls
Pediatric clinic closure risks
Low expected growth rate of 0.8-2%
👀 கவனிக்க வேண்டியவை
Monitor the dividend credit timeline and track the execution of the 'three-pronged strategy' involving specialty science and hybrid go-to-market models in upcoming quarterly results.
₹204.47 Cr Q1 Net Profit: Pfizer Reports 6.6% YoY Growth in Bottom Line
Pfizer Limited reported a steady performance for the quarter ended June 30, 2026, with revenue from operations rising 8.3% YoY to ₹653.17 crore. Net profit increased by 6.6% to ₹204.47 crore, up from ₹191.75 crore in the corresponding quarter of the previous year. The company maintained strong profitability with a PAT margin of approximately 31.3%. Notably, there were no exceptional items this quarter, unlike the previous financial year which saw significant separation costs related to brand distribution shifts.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned into the new fiscal year with steady single-digit growth in revenue and profit, moving past the exceptional separation costs incurred in FY2025-26.
ஏன் இது முக்கியம்The results confirm Pfizer's ability to maintain high margins (31%+) and steady growth in the Indian market, supported by its shift toward a specialty and patented product portfolio.
📅 குறுகிய காலம்The stock is likely to remain stable or see mild positive interest as the results meet expectations for steady growth in the MNC pharma space.
📈 நீண்ட காலம்Pfizer's long-term value depends on its ability to introduce global patented drugs to India and leverage its hybrid sales model to expand market share in chronic and specialty therapies.
⚠ அபாய எச்சரிக்கைகள்
Concentration risk in specialty therapies
Regulatory pricing pressures on legacy brands
Dependency on parent company's global product pipeline
👀 கவனிக்க வேண்டியவை
Investors should monitor the volume growth in legacy brands following the distribution agreement with Cipla and watch for the launch of new patented products from Pfizer's global portfolio.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
CFO Amit Agarwal Resigns; Effective October 8, 2026
Pfizer Limited has announced the resignation of Mr. Amit Agarwal from his positions as Executive Director – Finance and Chief Financial Officer (CFO). The resignation is effective from the close of business on October 8, 2026, as he intends to pursue a professional opportunity outside the company. Mr. Agarwal will also vacate his seat on the Board of Directors and three key committees, including Risk Management and CSR. The company has approximately two and a half months to manage the transition for this Key Managerial Personnel (KMP) role.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. Amit Agarwal is stepping down as the CFO and Executive Director of Pfizer Limited to join another organization.
ஏன் இது முக்கியம்The CFO is a critical Key Managerial Personnel responsible for financial reporting and risk management; while routine in large MNCs, leadership stability is important for maintaining investor confidence.
Effective Date of Resignation: அக்டோபர் 8, 2026Net Worth: Rs 4203 கோடிகடன்: Rs 70 கோடிDec 2025 Quarterly Revenue: Rs 645.03 கோடிPromoter Holding: 63.92%
📅 குறுகிய காலம்The market is likely to react neutrally as the resignation is not immediate, allowing time for a successor search.
📈 நீண்ட காலம்Limited structural impact expected given Pfizer's established global systems and processes, provided a competent successor is appointed.
⚠ அபாய எச்சரிக்கைகள்
Potential for temporary leadership transition risk if a successor is not named before the October deadline
👀 கவனிக்க வேண்டியவை
Watch for the announcement of a successor to the CFO role to ensure continuity in financial oversight and strategic execution.
Pfizer announces Rs 75 per share final dividend; Record date set for July 17, 2026
Pfizer Limited has announced a final dividend of Rs 75 per equity share for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine shareholder eligibility for this payout. The 75th Annual General Meeting (AGM) is scheduled for July 28, 2026, via video conferencing. Dividend payments are expected to commence on or after August 4, 2026, subject to shareholder approval at the AGM.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the timeline for its annual dividend payout and the 75th Annual General Meeting.
ஏன் இது முக்கியம்The Rs 75 per share dividend represents a significant cash return to shareholders, reflecting a dividend yield of approximately 1.66% based on the current price of Rs 4527.
Final Dividend: Rs 75 per shareDividend Yield (approx): 1.66%ரெக்கார்ட் தேதி: ஜூலை 17, 2026AGM Date: ஜூலை 28, 2026Payment Date: ஆகஸ்ட் 4, 2026
📅 குறுகிய காலம்The stock may witness interest leading up to the record date of July 17 as investors seek to qualify for the Rs 75 dividend.
📈 நீண்ட காலம்Limited; this is a routine annual distribution of profits consistent with the company's historical payout practices.
👀 கவனிக்க வேண்டியவை
Shareholders should ensure their bank account and KYC details are updated with their Depository Participant or RTA by the July 17 record date to ensure seamless dividend credit.
₹75 Final Dividend Recommended; 75th AGM Scheduled for July 28, 2026
Pfizer Limited has issued a notice for its 75th Annual General Meeting (AGM) to be held on July 28, 2026. The Board has recommended a final dividend of ₹75 per equity share (750%) for FY 2025-26, with a record date of July 17, 2026. Key agenda items include the adoption of audited financial statements and the re-appointment of Mr. P. Rengan as Director. The company also disclosed transferring ₹1.65 crore in unclaimed dividends to the IEPF during the last financial year.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the timeline for its 75th AGM and the payout of its previously recommended ₹75 per share dividend.
ஏன் இது முக்கியம்The dividend represents a significant cash return to shareholders, yielding approximately 1.6% at current market prices, reflecting the company's strong cash position and low debt (₹70 Cr).
Final Dividend: ₹75 per shareDividend Percentage: 750%ரெக்கார்ட் தேதி: ஜூலை 17, 2026Unclaimed Dividend Transferred: ₹1.65 கோடிIEPF Share Balance: 4,34,170 யூனிட்கள்
📅 குறுகிய காலம்The stock is likely to remain supported in the near term as it approaches the dividend record date of July 17.
📈 நீண்ட காலம்Structural growth depends on the company's ability to launch new patented products from its global basket, as legacy brands face generic competition.
⚠ அபாய எச்சரிக்கைகள்
Dependency on hospital footfalls and pediatric clinic operations for revenue growth.
👀 கவனிக்க வேண்டியவை
Investors should ensure their bank details are updated by the record date of July 17, 2026, to receive the ₹75/share dividend. Watch for the full Annual Report for updates on the global patented product pipeline.
Pfizer Ltd Announces Final Dividend of Rs 75 per Share; Sets Record Date for July 17, 2026
Pfizer Limited has recommended a substantial final dividend of Rs. 75 per equity share for the financial year ended March 31, 2026. This represents a 750% payout on the face value of Rs. 10 per share. The company has officially fixed July 17, 2026, as the record date to determine the eligibility of shareholders for this payout. This announcement follows the board meeting held on May 12, 2026, reflecting a strong commitment to shareholder returns.
முக்கிய அம்சங்கள்
Recommended final dividend of Rs. 75 per equity share for FY 2025-26Dividend payout represents 750% of the face value of Rs. 10 per shareRecord date for determining dividend entitlement is fixed as July 17, 2026The recommendation was finalized during the Board of Directors meeting on May 12, 2026
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date, which is typically one business day prior to the July 17 record date. The high absolute dividend amount makes it an attractive proposition for yield-seeking investors.
Pfizer Limited Receives ₹85.74 Crore Income Tax Demand for FY 2022-23
Pfizer Limited has received an assessment order from the Income-tax Department for the financial year 2022-23, involving a tax demand of ₹85.74 crore. The demand stems from alleged under-reporting of income due to the disallowance of certain expenses in the company's tax returns. Additionally, the department has issued a show cause notice to initiate penalty proceedings. The company intends to contest the order through an appeal and believes it has strong legal grounds to defend its position.
முக்கிய அம்சங்கள்
Total tax demand amounting to ₹85,73,96,440 (₹85.74 crore) for FY 2022-23Order issued under section 143(3) read with sections 144C(3) & 144B of the Income Tax ActShow cause notice issued for penalty proceedings under section 274 read with section 270ACompany is evaluating the order and plans to file an appeal or application for stayManagement expects no immediate material impact on financial position or operations
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the company's appeal, as a final adverse ruling could impact cash flows, though the company currently maintains a strong legal stance.
Pfizer Ltd Q3 Net Profit Rises 11% YoY to ‡141.8 Cr; Revenue Up 20%
Pfizer Limited reported a strong 20% year-on-year growth in revenue from operations, reaching ‡645.03 crore for the quarter ended December 31, 2025. Despite an exceptional charge of ‡58.20 crore related to workforce restructuring and new labor code provisions, net profit grew by 11% to ‡141.84 crore. The company entered a strategic agreement with Cipla for the distribution of four key brands, leading to a one-time separation cost of ‡39.58 crore. Overall, the operational performance remains robust with a significant 19.7% improvement in nine-month profitability compared to the previous year.
முக்கிய அம்சங்கள்
Revenue from operations grew 19.9% YoY to ‡645.03 crore from ‡537.99 crore in the previous year.Net profit increased 11.2% YoY to ‡141.84 crore, overcoming a ‡58.20 crore exceptional charge.Exceptional items include ‡39.58 crore for personnel separation following a distribution deal with Cipla for four brands.A provision of ‡18.62 crore was recorded to account for the impact of the Government's New Labour Codes.Nine-month net profit stands at ‡522.61 crore, up significantly from ‡436.66 crore in the corresponding period last year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong double-digit revenue growth and the strategic partnership with Cipla which aims to optimize distribution for key brands. The one-time exceptional costs are non-recurring, indicating healthy underlying operational margins.
Pfizer Limited Signs 5-Year Exclusive Marketing Agreement with Cipla for Key Brands
Pfizer Limited has entered into a strategic 5-year exclusive agreement with Cipla Limited for the marketing and distribution of four major brands: Corex Dx, Corex LS, Dolonex, and Neksium in India. Under this partnership, Pfizer will continue to manufacture and supply these medicines while leveraging Cipla's extensive distribution network to enhance market reach. The transition will lead to a reduction in Pfizer's own field force, the financial impact of which will be disclosed in upcoming results. This move represents a significant shift in Pfizer's domestic commercial strategy to optimize operational efficiency.
முக்கிய அம்சங்கள்
Exclusive 5-year agreement with Cipla for marketing and distribution of Corex Dx, Corex LS, Dolonex, and Neksium.Pfizer retains all manufacturing, sourcing, and supply responsibilities for the specified brands.The arrangement involves no upfront consideration, with commercial terms agreed upon for ongoing supply.Move will result in a reduction of Pfizer's field force, with restructuring costs to be reported in ensuing results.Partnership aims to leverage Cipla's 3rd rank position in the Indian pharma market for better brand penetration.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming quarterly results for one-time restructuring costs related to the field force reduction and evaluate if this outsourcing model improves Pfizer's operating margins over the long term.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
